Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis

Oncogene volume 18, pages 3936–3943 (1999)Cite this article

Abstract

The tumor suppressor gene PTEN (MMAC1, TEP1) encodes a dual-specificity phosphatase and is considered a progression-associated target of genetic alterations in human gliomas. Recently, it has been reported that the introduction of wild type PTEN into glioma cells containing endogenous mutant PTEN alleles (U87MG, LN-308), but not in those which retain wild-type PTEN (LN-18, LN-229), causes growth suppression and inhibits cellular migration, spreading and focal adhesion. Here, we show that PTEN gene transfer has no effect on the chemosensitivity of the four cell lines. Further, a correlational analysis of the endogenous PTEN status of 12 human glioma cell lines with their sensitivity to seven different cancer chemotherapy drugs reveals no link between PTEN and chemosensitivity. In contrast, ectopic expression of wild type PTEN, but not the PTENG129R mutant, in PTEN-mutant gliomas markedly sensitizes these cells to irradiation and to CD95-ligand (CD95L)-induced apoptosis. PTEN-mediated facilitation of CD95L-induced apoptosis is associated with enhanced CD95L-evoked caspase 3 activity. Protein kinase B (PKB/Akt), previously shown to inhibit CD95L-induced apoptosis in nonglial COS7 cells, is inactivated by dephosphorylation. Interestingly, both PTEN-mutant U87MG and PTEN-wild-type LN-229 cells contain phosphorylated PKB constitutively. Wild-type PTEN gene transfer promotes dephosphorylation of PKB specifically in U87MG cells but not in LN-229 cells. Sensitization of U87MG cells to CD95L-apoptosis by wild-type PTEN is blocked by insulin-like growth factor-1 (IGF-1). The protection by IGF-1 is inhibited by the phosphoinositide 3-OH (PI 3) kinase inhibitor, wortmannin. Although PKB is a down-stream target of PI 3 kinase, the protection by IGF-1 was not associated with the reconstitution of PKB phosphorylation. Thus, PTEN may sensitize human malignant glioma cells to CD95L-induced apoptosis in a PI 3 kinase-dependent manner that may not require PKB phosphorylation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

Abbreviations

CD95L:

CD95 ligand

EGF:

epidermal growth factor

IGF-1:

insulin-like growth factor-1

PTEN:

pBP-PTEN-HA

PKB:

protein kinase B

PI (3,4,5)P3:

phosphatidylinositol 3,4,5-trisphosphate

PI(4,5)P2:

phosphatidylinositol 4,5-bisphosphate

PI 3-kinase:

phosphoinositide 3-OH kinase

PDGF:

platelet derived growth factor

PTENG129R-HA:

PTENG129R

(WM):

wortmannin

References

  • Baserga R. . 1995 Cancer Res. 55: 249–252.

  • Cheney I, Johnson D, Vaillancourt M-T, Avanzini J, Morimoto A, Demers G, Wills K, Shabram P, Bolen J, Tavtigian S and Bookstein R. . 1998 Cancer Res. 58: 2331–2334.

  • Crowder R and Freeman R. . 1998 J. Neurosci. 18: 2933–2943.

    Article  CAS  Google Scholar 

  • Downward J. . 1998 Curr. Biol. 10: 262–267.

  • Dudek H, Datta S, Franke T, Birnbaum M, Yao R, Cooper G, Segal R, Kaplan D and Greenberg M. . 1997 Science 275: 661–665.

    Article  CAS  Google Scholar 

  • Duerr E-M, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis D, Schramm J, Wiestler O, Parsons R, Eng C and Deimling v A. . 1998 Oncogene 16: 2259–2264.

    Article  CAS  Google Scholar 

  • Furnari F, Lin H, Huang H-J and Cavenee W. . 1997 Proc. Natl. Acad. Sci. USA 94: 12479–12484.

  • Häusler P, Papoff G, Eramo A, Reif K, Cantrell D and Ruberti G. . 1998 Eur. J. Immunol. 28: 57–69.

    Article  Google Scholar 

  • Li D-M and Sun H. . 1997 Cancer Res. 57: 2124–2129.

  • Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner S, Giovanella B, Ittmann M, Tycko B, Hibshoosh H, Wigler M and Parsons R. . 1997 Science 275: 1943–1947.

  • Liu W, James C, Frederick L, Alderete B and Jenkins R. . 1997 Cancer Res. 57: 5254–5257.

  • Maehama T and Dixon J. . 1998 J. Biol. Chem. 273: 13375–13378.

    Article  CAS  Google Scholar 

  • Marte B and Downward J. . 1997 Trends Biochem. Sci. 22: 355–358.

  • Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R and Tonks NK. . 1997 Proc. Natl. Acad. Sci. USA 94: 9052–9057.

  • Rhei E, Kang L, Bolomolniy F, Federici M, Borgen P and Boyd J. . 1997 Cancer Res. 57: 3657–3759.

  • Rieger J, Naumann U, Glaser T, Ashkenazi A and Weller M. . 1998 FEBS Letts 427: 124–128.

  • Roth W, Fontana A, Trepel M, Dichgans J, Reed JC and Weller M. . 1997 Cancer Immunol. Immunother. 44: 55–63.

  • Schulz JB, Bremen D, Reed JC, Lommatzsch J, Takayama S, Wüller U, Löschmann P-A, Klockgether T and Weller M. . 1997 J. Neurochem. 69: 2075–2086.

  • Tamura M, Gu J, Matsumoto K, Aota S-i, Parsons R and Yamada K. . 1998 Science 280: 1614–1617.

    Article  CAS  Google Scholar 

  • Teng D-F, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen K, Vinson V, Gumpper K, Ellis L, El-Nagger A, Frazier M, Jasser S, Langford L, Lee J, Mills G, Pershouse M, Pollack R, Tornos C, Troncoso P, Yung W, Fujii G, Berson A, Bookstein R, Bolen J, Tavtigian S and Steck P. . 1997 Cancer Res. 57: 5221–5225.

  • Wang S, Puc J, Li J, Bruce J, Cairns P, Sidransky D and Parsons R. . 1997 Cancer Res. 57: 4183–4186.

  • Weller M, Frei K, Groscurth P, Krammer PH and Yonekawa Y. . 1994 J. Clin. Invest. 94: 954–964.

    Article  CAS  Google Scholar 

  • Weller M, Rieger J, Grimmel C, Van Meir E, De Tribolet N, Krajewski S, Reed J, Von Deimling A and Dichgans J. . 1998 Int. J. Cancer 79: 1–5.

    Article  CAS  Google Scholar 

  • Weller M, Trepel M, Grimmel C, Schabet M, Bremen D, Krajewski S and Reed JC. . 1997 Neurol. Res. 19: 459–470.

Download references

Acknowledgements

Supported by the German Research Foundation (We 1502/5-2) and the IKFZ Tübingen

Author information

Authors and Affiliations

  1. Department of Neurology, University of Tübingen, Hoppe-Seyler-Str. 3, Tübingen, 72076, Germany

    Wolfgang Wick, Ulrike Naumann & Michael Weller

  2. Ludwig Institute for Cancer Research, University of Calif-ornia at San Diego, La Jolla, California, 92093-0660, CA, USA

    Frank B Furnari & Webster K Cavenee

  3. Cancer Center, University of California at San Diego, La Jolla, California, 92093-0660, CA, USA

    Webster K Cavenee

Authors
  1. Wolfgang Wick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank B Furnari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulrike Naumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Webster K Cavenee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Weller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wick, W., Furnari, F., Naumann, U. et al. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene 18, 3936–3943 (1999). https://doi.org/10.1038/sj.onc.1202774

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202774

Keywords

This article is cited by

Search

Advanced search

Quick links